9-(DIFLUOROMETHOXY)-3,4-DIMETHOXY-5H-PYRIDO(1',2':4,5)(1,2,4)THIADIAZINO(2,3-A)BENZIMIDAZOL-13-IUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H14F2N3O3S
Molecular Weight	366.362
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure of 9-(DIFLUOROMETHOXY)-3,4-DIMETHOXY-5H-PYRIDO(1',2':4,5)(1,2,4)THIADIAZINO(2,3-A)BENZIMIDAZOL-13-IUM

Structure Search

SMILES

COC1=CC=[N+]2C3=NC4=C(C=C(OC(F)F)C=C4)N3SCC2=C1OC

InChI

InChIKey=MKKLIANODHXTFO-UHFFFAOYSA-N

InChI=1S/C16H14F2N3O3S/c1-22-13-5-6-20-12(14(13)23-2)8-25-21-11-7-9(24-15(17)18)3-4-10(11)19-16(20)21/h3-7,15H,8H2,1-2H3/q+1

HIDE SMILES / InChI

Molecular Formula	C16H14F2N3O3S
Molecular Weight	366.362
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11402494 | https://www.ncbi.nlm.nih.gov/pubmed/24301963

Pantoprazole is a proton pump inhibitor that inhibits gastric acid secretion and used for short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease. Pantoprazole suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours. Pantoprazole is used for short-term treatment of erosion and ulceration of the esophagus for adults and pediatric patients 5 years of age and older caused by gastroesophageal reflux disease. It can be used as a maintenance therapy for long-term use after initial response is obtained, but there have not been any controlled studies about the use of pantoprazole past a duration of 12 months. Pantoprazole may also be used in combination with antibiotics to treat ulcers caused by Helicobacter pylori. Use of pantoprazole may increase the chance of developing infections such as pneumonia, particularly in hospitalized patients.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18536934 \| https://www.ncbi.nlm.nih.gov/pubmed/8389196	Inhibitor 8297
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11402494	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erosive esophagitis associated with gastroesophageal reflux disease 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 8429	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 2000
Zollinger-Ellison syndrome 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 8429	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 2000

C_max

Value	Dose	Co-administered	Analyte	Population
2.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781 substrate 1737	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP2 383 OAT3 642 CYP2C8 911 CYP1A2 1524 CYP2A6 707 CYP2E1 882 P-gp 1461 BCRP 699 CYP2C19 1478 OAT1 599 OATP1B1 788 OATP1B3 706 OCT1 512 OCT2 647 OCT3 150 ALDH1 40 MATE2 263 MATE1 306 OATP2B1 123	CYP2C19 991 P-gp 1537 sulfotransferases 38	CYP1A 56 CYP1A1 108 CYP2C 15

Drug as perpetrator

Target	Modality	Activity
ALDH1 40	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNTc3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	inconclusive [Activation 22.3872 uM]
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19139163/	likely
CYP1A2 1692	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6Ilx0Q0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
MATE2 263	inhibitor 3277 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >500 uM]
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	no
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	no
OATP2B1 126	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
CYP2C19 1553	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00213 \| https://drug-interactions.medicine.iu.edu/MainTable.aspx \| https://pubmed.ncbi.nlm.nih.gov/21795468/	weak [IC50 93 uM]
P-gp 1650	inhibitor 3277 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes [IC50 17.9 uM]
OCT2 648	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 2.8 uM]
OCT3 150	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 22.9 uM]
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 30.8 uM]
OAT3 644	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 4.45 uM]
MATE1 308	inhibitor 3277 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	yes [IC50 43.2 uM]
BCRP 773	inhibitor 3277 Sources: https://go.drugbank.com/articles/A16380 \| https://pubmed.ncbi.nlm.nih.gov/19076159/	yes [IC50 5.5 uM]
OAT1 603	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 63.21 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15258107/	yes [Ki 6.5 uM]
CYP1A 121	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=21 Page: (Pharm_P7) 21	yes
CYP1A1 218	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/	yes
CYP2C 34	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
MRP2 475	activator 214 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	yes
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OCT3 150	activator 214 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/	yes

Drug as victim

Target	Modality	Activity
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 \| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C29346&ns=ncit&type=relationship&key=n75796996&b=1&n=0&vse=null Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
P-gp 1537	substrate 3367 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes
sulfotransferases 38	substrate 3367 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=102625707 \| https://pubmed.ncbi.nlm.nih.gov/9165689/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7915	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7915
ChemicalBook	CB51025809	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51025809
ChemicalBook	CB8129842	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8129842
MolPort	MolPort-003-666-752	https://www.molport.com/shop/molecule-link/MolPort-003-666-752
MolPort	MolPort-005-933-577	https://www.molport.com/shop/molecule-link/MolPort-005-933-577
eMolecules	902267	https://www.emolecules.com/cgi-bin/more?vid=902267

PubMed

Title	Date	PubMed
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.	2001	11768559
Lansoprazole: an update of its place in the management of acid-related disorders.	2001	11693467
Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction.	2001 Aug	11558857
Dyspepsia: challenges in diagnosis and selection of treatment.	2001 Aug	11558854
Resolution of Menetrier's disease after Helicobacter pylori eradication therapy.	2001 Aug 24	11589437
Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects.	2001 Dec	11827362
Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.	2001 Dec	11774936
Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome.	2001 Dec	11773945
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.	2001 Dec	11770010
Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia.	2001 Dec	11736723
Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial).	2001 Dec 17	11802510
Six regimens for the eradication of Helicobacter pylori (Hp) in duodenal ulcer patients: three consecutive trials (1995-1999).	2001 Jan-Dec	11595472
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.	2001 Jul	11519776
Persistent eradication of Helicobacter pylori after systemic politherapy associated with periodontal pockets treatment with metronidazole and calcium sulphate.	2001 Jul-Aug	12067080
Cluster headache without autonomic symptoms?	2001 Nov	11903290
Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease.	2001 Nov	11685025
Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux.	2001 Oct	11718254
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.	2001 Oct	11695354
Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis.	2001 Oct	11563998
Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis.	2001 Sep	11552908
[Comparative study of proton pump inhibitors].	2001 Sep 9	11680100
[Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].	2002	12353402
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.	2002	12222994
Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate.	2002	12060043
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].	2002	12043311
Selective colonization by Helicobacter pylori of the deep gastric glands and intracellular canaliculi of parietal cells in the setting of chronic proton pump inhibitor use.	2002 Apr	11943964
Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.	2002 Apr	11929403
Pantoprazole IV (Protonix IV).	2002 Apr 29	11981511
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.	2002 Aug	12182745
Nonallergic anaphylaxis to pantoprazole.	2002 Feb	11929432
Protonix. First i.v. proton pump inhibitor approved.	2002 Feb	11924161
The novel use of an intravenous proton pump inhibitor in a patient with short bowel syndrome.	2002 Jan	11743248
Enantiomeric determination of pantoprazole in human plasma by multidimensional high-performance liquid chromatography.	2002 Jan 5	11824393
Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice.	2002 Jul	12177723
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.	2002 Jul	12152007
Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.	2002 Jul 15	12119060
Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection.	2002 Jul-Aug	12143188
Pantoprazole-induced recurrent anaphylactic shock.	2002 Jun	12094902
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.	2002 Jun	12030958
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.	2002 Jun 22	12077038
[Correlation of Barrett's esophagus and colonic adenomas].	2002 Jun 9	12132329
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.	2002 Mar	11876710
Acid suppression in healthy subjects following lansoprazole or pantoprazole.	2002 Mar	11876695
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.	2002 Mar	11849125
Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.	2002 May	12017345
Combination drug therapy for gastroesophageal reflux disease.	2002 May	11978171
Stability of pantoprazole in an extemporaneously compounded oral liquid.	2002 May 15	12040734
Factors associated with treatment failure of Helicobacter pylori infection in a developing country.	2002 Oct	12352294
Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.	2002 Oct 21	12381251
Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux.	2002 Sep	12395996

Patents

Sample Use Guides

In Vivo Use Guide

Oral use: Short-Term Treatment of Erosive Esophagitis Associated With GERD: 40 mg Once daily for up to 8 weeks; Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: 40 mg Twice daily IV: The recommended adult dose is 40 mg pantoprazole given once daily by intravenous infusion for 7 to 10 days

Route of Administration: Other

In Vitro Use Guide

To determine "ex vivo" gastric mucosa gastric acid secretion, pantoprazole (as DMSO solution diluted with serosal fluid) was added to membrane mucosa liquid in the bath tube. Pantoprazole final concentration in serosal fluidwas 5 mkM, incubation time -- 2.5h. Pantoprazole mediated gastric acid secretion inhibition is 24.3% at 5mkM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 14:24:50 GMT 2023` Edited by `admin` on `Sat Dec 16 14:24:50 GMT 2023`
Record UNII	U5H68DGQ8L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

9-(DIFLUOROMETHOXY)-3,4-DIMETHOXY-5H-PYRIDO(1',2':4,5)(1,2,4)THIADIAZINO(2,3-A)BENZIMIDAZOL-13-IUM

Systematic Name

English

5H-PYRIDO(1',2':4,5)(1,2,4)THIADIAZINO(2,3-A)BENZIMIDAZOL-13-IUM, 9-(DIFLUOROMETHOXY)-3,4-DIMETHOXY-

Systematic Name

English

PANTOPRAZOLE METABOLITE ACTIVE SULFENAMIDE

Common Name

English

Code System Code Type Description

PUBCHEM

15163517

Created by admin on Sat Dec 16 14:24:51 GMT 2023 , Edited by admin on Sat Dec 16 14:24:51 GMT 2023

PRIMARY

CAS

138786-74-0

Created by admin on Sat Dec 16 14:24:51 GMT 2023 , Edited by admin on Sat Dec 16 14:24:51 GMT 2023

PRIMARY

FDA UNII

U5H68DGQ8L

Created by admin on Sat Dec 16 14:24:51 GMT 2023 , Edited by admin on Sat Dec 16 14:24:51 GMT 2023

PRIMARY

Related Record Type Details


					U5H68DGQ8L

9-(DIFLUOROMETHOXY)-3,4-DIMETHOXY-5H-PYRIDO(1',2':4,5)(1,2,4)THIADIAZINO(2,3-A)BENZIMIDAZOL-13-IUM

IONIC MOIETY

Amount:

Related Record Type Details


					D8TST4O562

PANTOPRAZOLE

PRODRUG -> METABOLITE ACTIVE

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdfCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11402494 | https://www.ncbi.nlm.nih.gov/pubmed/24301963

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11402494 | https://www.ncbi.nlm.nih.gov/pubmed/24301963

C_max

T_1/2

Drug as perpetrator